HomeStock ScreenerValiant Laboratories

Valiant Laboratories Current Share Price | Valiant Laboratories Stock Screener

VALIANTLAB Pharmaceuticals
Live Share Price NSE
₹107.87
▲ 2.39 (2.27%)
2026-08-26 00:00:00
Live Share Price BSE
₹124.71
▲ 2.12 (1.73%)
2026-09-18 00:00:00
As of August 26, 2026, the live Valiant Laboratories share price (NSE: VALIANTLAB) is ₹107.87 on NSE and ₹124.71 on BSE, up 2.27% from the previous close, with shares trading between ₹103.32 and ₹110.70 in today's trading session, and a 52-week range of ₹50.93–₹107.87. Browse VALIANTLAB income statement to support your investment research. Use the Valiant Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Valiant Laboratories Market Cap ₹666.03 Cr.
VALIANTLAB P/E Ratio (TTM) 43.21
Valiant Laboratories P/B Ratio 2.18
EPS (TTM) ₹-0.51
Dividend Yield -
Debt to Equity 0.42
VALIANTLAB 52 Week High ₹107.87
Valiant Laboratories 52 Week Low ₹50.93
Operating Margin 25.00%
Profit Margin 18.10%
VALIANTLAB Revenue (TTM) ₹116.00
EBITDA ₹30.00
Net Income ₹21.00
Total Assets ₹464.00
Total Equity ₹311.00

Valiant Laboratories Current Share Price Chart

Track the current Valiant Laboratories share price and stock price with an interactive chart. Analyse VALIANTLAB price trends, trading volume, historical performance, and volatility across different timeframes — the complete Valiant Laboratories stock quote in one place.

Valiant Laboratories Company Profile - Fundamental Screener

Screen Valiant Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VALIANTLAB shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE0JWS01017

Valiant Laboratories Balance Sheet Screener

Screen VALIANTLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023
Assets
Total Assets 464 401 343 213
Current Assets 228 193 226 151
Fixed Assets 233 48 50 48
Liabilities
Total Liabilities 0 0 0 0
Current Liabilities 34 107 77 62
Non-Current Liabilities 0 0 0 0
Shareholders' Equity
Total Equity 311 234 237 101
Share Capital 54 44 44 33
Reserves & Surplus 257 191 193 68

Valiant Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Valiant Laboratories income statement and profit fundamentals. Analyze VALIANTLAB quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Valiant Laboratories share price evaluation.
Item 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec
Revenue 116 92 53 47 48 56 37 25 22 33 42 63 54 92 72
Expenses 86 87 53 46 44 54 35 28 21 35 47 61 48 81 61
EBITDA 30 5 0 1 3 2 2 -3 0 -2 -5 2 6 10 11
Operating Profit % 25.00% 5.00% -2.00% 0.00% 5.00% 7.00% 2.00% -31.00% -13.00% -15.00% -16.00% -2.00% 7.00% 10.00% 14.00%
Depreciation 3 3 2 1 1 1 1 1 1 1 1 1 1 0 0
Interest 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 26 1 -3 0 3 1 2 -4 0 -3 -5 1 6 10 10
Tax 5 -1 4 0 1 0 -1 1 0 -1 -2 0 2 2 3
Net Profit 21 2 -7 0 2 1 2 -5 -1 -1 -4 1 4 8 8
EPS 3.89 0.32 -1.30 0.04 0.42 0.16 0.54 -1.09 -0.13 -0.33 -0.81 0.24 1.31 2.41 4.70

Valiant Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen VALIANTLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March
Operating Activities 1 2 56
Investing Activities -53 -144 -55
Financing Activities 45 152 -1
Net Cash Flow -7 11 0

Valiant Laboratories Shareholding Pattern Screener

See Valiant Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Valiant Laboratories promoter holding and ownership changes for VALIANTLAB on TickJournal.
Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Aug 2025-Sept 2025-Dec 2024-Mar
Promoter Holding 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94% 74.94%
FII Holding 0.20% 0.00% 0.64% 0.63% 0.52% 0.02% 0.01% 3.48%
DII Holding 0.00% 0.00% 0.00% 0.46% 0.00% 0.00% 0.00% 0.03%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 18.53% 18.91% 16.28% 17.05% 17.08% 18.19% 18.51% 15.16%
Other Holding 6.33% 6.15% 8.13% 6.92% 7.46% 6.85% 6.55% 6.39%
Shareholder Count 14,657 14,341 15,036 14,432 14,948 15,075 14,910 14,914

Valiant Laboratories Share Dividend Screener - Share Yield Analysis

Check Valiant Laboratories dividend history with payout and yield data. View Valiant Laboratories dividend details including ex-dates and amounts for VALIANTLAB stock.
No dividends declared by Valiant Laboratories.

Valiant Laboratories Stock Index Membership

See which indices include Valiant Laboratories stock. Check VALIANTLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Valiant Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Valiant Laboratories Market Events Screener - Corporate Actions

Get Valiant Laboratories corporate actions including splits, bonuses, and buybacks. Check Valiant Laboratories stock events that may affect VALIANTLAB share price.
Announcement Date Record Date Event Type Information Price Impact
2026-09-28 2026-09-28 Annual General Meeting NA 26.87%
2026-08-10 2026-08-10 Quarterly Result Announcement NA 1.14%
2026-05-14 2026-05-14 Quarterly Result Announcement NA -1.81%
2026-02-11 2026-02-11 Quarterly Result Announcement NA 8.90%
2025-11-11 2025-11-11 Quarterly Result Announcement NA -1.09%
2025-09-25 2025-09-25 Annual General Meeting NA 1.55%
2025-08-08 2025-08-08 Quarterly Result Announcement NA 3.60%
2025-07-18 2025-07-19 Rights 1:4 -1.43%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 3.47%
2025-02-07 2025-02-07 Quarterly Result Announcement NA 6.48%
2024-11-12 2024-11-12 Quarterly Result Announcement NA -3.59%
2024-08-08 2024-08-08 Annual General Meeting NA -13.18%

Valiant Laboratories Competitors Screener - Peer Comparison

Screen VALIANTLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 440,278 36.48 61,674 12.69% 11,565 33.19
Divis Laboratories 244,178 84.64 11,067 13.95% 2,568 59.21
Torrent Pharmaceuticals 184,478 87.77 13,886 20.34% 2,138 44.26
Zydus Life Science 110,585 24.32 27,658 17.64% 5,026 41.59
Cipla 109,140 32.86 29,045 2.24% 3,870 32.08
Laurus Labs 104,025 97.64 6,868 22.01% 890 60.27
Dr Reddys Laboratories 95,570 30.44 35,059 3.90% 4,158 41.23
Aurobindo Pharma 95,513 25.98 34,145 5.56% 3,503 53.00
Lupin 94,336 17.27 29,039 26.75% 5,356 24.64
Mankind Pharma 94,184 45.49 14,636 14.85% 1,938 37.66

Valiant Laboratories Company Announcements - News Screener

Screen VALIANTLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-09-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-03 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-09-03 Letter To Shareholders -
2026-09-03 Notice Of 5Th Annual General Meeting And Annual Report For FY 2025-26 -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-08-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-12 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-10 Announcement under Regulation 30 (LODR)-Monitoring Agency Report -
2026-08-10 Opening Of A New Corporate Office Of The Company -
2026-08-10 Announcement under Regulation 30 (LODR)-Change in Registered Office Address -
2026-08-10 Announcement under Regulation 30 (LODR)-Acquisition -
2026-08-10 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-08-10 For Quarter Ended June 30 2026. -
2026-08-10 Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter Ended June 30 2026. -
2026-08-05 Board Meeting Intimation for Approval Of Financial Results For Quarter Ended June 30 2026 -
2026-07-13 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-06-26 Closure of Trading Window -
2026-05-30 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-05-22 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-20 Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 -